Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2005
12/01/2005WO2005089733A3 Anti-adhesive compounds to prevent and treat bacterial infections
12/01/2005WO2005087207B1 Compositions and methods for the treatment of depression and other affective disorders
12/01/2005WO2005085240A3 Process for the preparation of ziprasidone
12/01/2005WO2005084686A3 Boronate medicaments for preventing thrombosis during surgery
12/01/2005WO2005084129A8 Structured triglycerides and emulsions comprising same
12/01/2005WO2005080406A3 Compounds for the inhibition of undesired cell proliferation and use thereof
12/01/2005WO2005079767A3 Means for modulation of the effects of opioid-like substances
12/01/2005WO2005078125A3 Itpase gene polymorphisms associated with adverse drug reactions to azathioprine therapy
12/01/2005WO2005078090A3 Antisense oligonucleotides for treating unwanted pigmentation of the skin and hair
12/01/2005WO2005077365A3 Novel uses for proton pump inhibitors
12/01/2005WO2005076899A3 Oral androgen therapy using modulators of testosterone bioavailablity
12/01/2005WO2005075467A3 Crystalline forms of zolmitriptan
12/01/2005WO2005074985A3 Methods of modulating cd200 and cd200r
12/01/2005WO2005072722A3 Method of using punicic acid to enhance immune response and prevent metabolic disorders
12/01/2005WO2005067927A3 The use of quaternary pyridinium salts as vasoprotective agents
12/01/2005WO2005067901A3 Methods for treating and preventing hypertension and hypertension-related disorders
12/01/2005WO2005065721A3 Use of an anti-inflammatory compound for the reduction of inflammation secondary to the administration of a lipid-nucleic acid complex
12/01/2005WO2005065192A3 Photolabile compounds
12/01/2005WO2005060963A8 Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
12/01/2005WO2005053650A8 Azithromycin dosage forms with reduced side effects
12/01/2005WO2005044225A3 Process for production of essentially solvent-free small particles
12/01/2005WO2005042516A3 Ligands of melanocortin receptors and compositions and methods related thereto
12/01/2005WO2005040176A3 Methods for the preparation of {2-[8,9-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl}phosphonic acid and esters thereof
12/01/2005WO2005038037A3 Methods for preparing phospholipids containing omega-3 and omega-6 moieties
12/01/2005WO2005037195A3 Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
12/01/2005WO2005025487A3 Oligonucleotides targeting prion diseases
12/01/2005WO2005023196A3 Compounds and methods
12/01/2005WO2005019167A3 Melanin concentrating hormone receptor antagonist
12/01/2005WO2005011642A9 Single unit pharmaceutical composition comprising a mixture of a fibrate and an homocysteine reducing agent
12/01/2005WO2005007124A3 Substituted dihydropyrimidine inhibitors of calcium channel function
12/01/2005WO2004108715A8 3-aryloxy and 3-heteroaryloxy substituted benzo(b) thiophenes as therapeutic agents with pi3k activity
12/01/2005WO2004108713A8 Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents
12/01/2005WO2004101544A8 Benzyl sulfonamide derivatives as androgen receptor antagonists
12/01/2005WO2004096118B1 Composition for improving cognition and memory
12/01/2005WO2004080964A8 Indole derivatives useful for the treatment of diseases
12/01/2005WO2004075845A3 Methods for treating or preventing autoimmune disease using histamine h1 receptor-blocking agents
12/01/2005WO2004071384A3 New pharmaceutical compositions based on anticholinergics and tace-inhibitors
12/01/2005WO2004064775A3 Sigma-2 receptor agonists and their use in the treatment of hiv infection
12/01/2005WO2004037289A3 Novel injectable depot formulations
12/01/2005WO2004026280A3 Granulate formulation of the rapamycin ester cci-779
12/01/2005WO2004020979A3 Methods of assaying for cell cycle modulators using components of the ubiquitin ligation cascade
12/01/2005WO2004010929A3 METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-β INHIBITORS
12/01/2005WO2003075832A3 Methods and composition based on discovery of metabolism of nitroclycerin
12/01/2005WO2003027632A3 Use of isogenic human cancer cells for high-throughput screening and drug discovery
12/01/2005US20050267340 In-vivo information measurement apparatus
12/01/2005US20050267304 Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders
12/01/2005US20050267301 Production of high molecular weight hyaluronates
12/01/2005US20050267221 Use of curcumin and analogues thereof as inhibitors of ACC2
12/01/2005US20050267220 Methods for inhibiting activity of polyamine transporters
12/01/2005US20050267219 Enantiomers of N-desmethyl venlafaxine
12/01/2005US20050267217 Methods and devices for preventing transmission of sexually transmitted diseases
12/01/2005US20050267216 suspending or forming a slurry of the R enantiomer of albuterol dibenzoyl tartrate complex in at least one solvent;adding hydrogen chloride in a C1-C4 alcohol to the suspension or slurry until levalbuterol hydrochloride Polymorph B is obtained
12/01/2005US20050267215 Abca-1 elevating compounds
12/01/2005US20050267214 Containing a quinolinecarbonylalkyl group, e.g., N1-[3-[(butylamino)sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl) amino]butanediamide
12/01/2005US20050267213 Use of photodynamic therapy to enhance treatment with immuno-modulating agents
12/01/2005US20050267212 Omega-3 fatty acids in the treatment of depression
12/01/2005US20050267211 Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense
12/01/2005US20050267209 urea and isomorphs consisting of phenylalanine, tyrosine, cinnamic acid, hippuric acid, procaine, resveratrol, tryptophan, 5-fluorouracil and uracil; bioavailability
12/01/2005US20050267208 Nordihydroguaiartic derivatives for use in treatment of tumors
12/01/2005US20050267207 Thyronamine derivatives and analogs and methods of use thereof
12/01/2005US20050267206 Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
12/01/2005US20050267205 2,4-dihydroxybenzoic acid derivatives
12/01/2005US20050267204 Synergistic gold-containing compositions
12/01/2005US20050267203 Carbamate compounds for use in preventing or treating anxiety disorders
12/01/2005US20050267202 Chromanol derivatives, a process for their production and their use as anti-inflammatory agents
12/01/2005US20050267201 Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
12/01/2005US20050267200 Heteroaromate OSC inhibitors
12/01/2005US20050267199 2-Amino- and 2-thio- substituted 1,3-diaminopropanes
12/01/2005US20050267198 Novel processes for preparing amorphous atorvastatin hemi-calcium
12/01/2005US20050267197 Compositions containing policosanol and HMG-Co-A reductase inhibitor and their pharmaceutical uses
12/01/2005US20050267196 Reducing tumor necrosis factor; phosphodiesterase inhibitor; anticancer agents; antidepressants; antiinflammatory agents; skin dsorders; antidepressants
12/01/2005US20050267195 Drug composition for blood sugar control
12/01/2005US20050267194 Indole compounds
12/01/2005US20050267193 Diindolylmethane formulations for the treatment of leiomyomas
12/01/2005US20050267192 Growing strain NPS012745 in a culture and recovering bis- indole pyrroles from it
12/01/2005US20050267191 Process for producing a dipeptidyl peptidase IV inhibitor
12/01/2005US20050267190 Solid-state form of celecoxib having enhanced bioavailability
12/01/2005US20050267189 Celecoxib compositions
12/01/2005US20050267187 Reacting free hydroxyl-containing probucol or a derivative thereof (by which is meant a probucol compound with at least one substituent that is different from that on the parent probucol molecule but which maintains the two free hydroxyl groups) with a Grignard reagent or a lithium reagent
12/01/2005US20050267186 Minimal cardivascular and/or sedatory activity; treating pain and allodynia; selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors;
12/01/2005US20050267185 1,2,4-triazole derivatives, compositions, process of making and methods of use
12/01/2005US20050267183 Selective estrogen receptor modulators
12/01/2005US20050267182 Urea derivatives as FLT-3 modulators
12/01/2005US20050267181 Mixtures of a modified group A streptogramin containing an oxazole ring with a natural, semi-synthetic or synthetic group B streptogramin, e.g., pristinamycin IA, pristinamycin IB, IC, ID, IE, IF, or IG; virginiamycin S1, S3, S4, B, or C; or etamycin; low toxicity
12/01/2005US20050267180 treatment/prevention of non-insulin dependent diabetes mellitus, lowing cholesterol, decrease blood pressure, counteract inflammatory atherosclerosis, metabolic disorders, polycystic ovary syndrome, liver disorders; S)-2-Ethoxy-3-[2-methyl-4-(5-methyl-2-o-tolyl-oxazol-4-ylmethoxy)-phenyl]-propionic acid
12/01/2005US20050267179 Novel thioether derivatives
12/01/2005US20050267177 Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
12/01/2005US20050267176 Dopamine-agonist combination therapy for improving sleep quality
12/01/2005US20050267175 Anticancer agents for, lungs, leukemia and ovarian cancer or prostate glands
12/01/2005US20050267173 Serine protease inhibitors
12/01/2005US20050267172 Use in reducing unwanted side effects of chemo- or radiotherapy of cancer, improving cardiovascular function, preventing mutagenesis, preventing initiation or progression of cancer, reducing toxic consequences of radiation exposure
12/01/2005US20050267171 Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
12/01/2005US20050267170 Substituted methyl aryl or heteroaryl amide compounds
12/01/2005US20050267168 Pentanoic acid derivatives
12/01/2005US20050267167 Pentanoic acid derivatives
12/01/2005US20050267166 Binding to the colchicne sites of tubulin sub units for treatment of cancer, alopecia and neutropenia
12/01/2005US20050267165 Il-8 receptor antagonists
12/01/2005US20050267164 1-(Hetero)aryl- and 3-substituted with a group containing an arylaldehyde oxime, e.g., 4-[5-(2-oxo-3-pyridin-4-yl-imidazolidin-1-yl)-pentyloxy]-benzaldehyde O-methyl-oxime; treating enteroviral infections
12/01/2005US20050267163 Vanilloid receptor ligands and their use in treatments
12/01/2005US20050267162 Hydrochloride salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
1 ... 4448 4449 4450 4451 4452 4453 4454 4455 4456 4457 4458 4459 4460 4461 4462 4463 4464 4465 4466 4467 4468 ... 7860